A new investigational anticoagulant called Asundexian is drawing major attention in stroke research.
Results from the OCEANIC-STROKE trial, presented at the International Stroke Conference (ISC) 2026, suggest that this once-daily oral medication could significantly reduce the risk of recurrent ischemic stroke without increasing major bleeding — a balance that has long been difficult to achieve in stroke prevention.
In a large global trial involving 12,327 patients across 37 countries, Asundexian reduced the risk of recurrent stroke by 26% when added to standard antiplatelet therapy.
If future approvals follow, this drug may represent an important step forward in secondary stroke prevention, particularly for patients with noncardioembolic ischemic stroke.
Why Stroke Prevention Still Needs Better Blood Thinners
Preventing another stroke after the first event remains a major challenge in neurology.
Patients who experience noncardioembolic ischemic stroke are usually treated with antiplatelet medications such as aspirin or clopidogrel. These drugs reduce clot formation but do not eliminate the risk entirely.
Attempts to intensify treatment with stronger anticoagulants have historically run into a major problem:
More powerful clot prevention usually leads to higher bleeding risk.
Traditional anticoagulants like:
- warfarin
- apixaban
- rivaroxaban
work by blocking key parts of the clotting cascade. While this helps prevent harmful clots that cause stroke, it also interferes with the body’s ability to stop normal bleeding.
This trade-off has limited how aggressively doctors can treat patients at risk of recurrent stroke.
How Asundexian Works Differently
Asundexian takes a more targeted approach.
Instead of blocking the entire clotting cascade, the drug selectively inhibits Factor XIa, a component believed to play a larger role in abnormal clot formation than in normal bleeding control.
Research has shown that people with naturally low levels of Factor XI tend to have lower rates of stroke and thrombosis, without experiencing significantly higher bleeding complications.
Because of this biology, researchers have long suspected that Factor XI inhibitors could prevent dangerous clots while preserving normal hemostasis.
Asundexian is one of the first drugs to test this concept in a large stroke prevention trial.
In simple terms, older anticoagulants shut down the entire alarm system to stop false alarms.
Asundexian aims to disable only the faulty sensor responsible for excessive clotting.
OCEANIC-STROKE Trial Results
The OCEANIC-STROKE trial evaluated Asundexian in patients who recently experienced:
- mild-to-moderate noncardioembolic ischemic stroke
- or high-risk transient ischemic attack (TIA)
All participants were already receiving standard antiplatelet therapy.
Key findings after two years
Recurrent ischemic stroke
- 6.2% with Asundexian
- 8.4% with placebo
- 26% relative risk reduction
Disabling or fatal stroke
- 2.1% with Asundexian
- 3.0% with placebo
- 31% reduction
Major bleeding (ISTH definition)
- 1.9% with Asundexian
- 1.7% with placebo
- No significant increase
Researchers also observed a 17% reduction in the combined risk of cardiovascular death, myocardial infarction, or stroke.
Importantly, treatment benefits appeared within weeks of starting therapy and continued throughout the two-year study period.
The positive effect remained consistent across multiple subgroups, including:
- different age groups
- men and women
- stroke severity levels
- different antiplatelet regimens
Which Stroke Patients Could Benefit From Asundexian?
The study focused on patients with:
- noncardioembolic ischemic stroke
- NIHSS score ≤15
- high-risk TIA (ABCD2 score ≥6)
- treatment initiated within 72 hours of stroke onset
These patients represent a large proportion of individuals seen in stroke clinics and hospitals.
However, the drug is not intended for cardioembolic stroke, such as strokes caused by atrial fibrillation (AF). Those patients already have established anticoagulation options.
Instead, Asundexian may help fill a long-standing treatment gap in patients whose strokes are not caused by heart rhythm disorders.
Is Asundexian Approved Yet?
Not yet.
Asundexian is currently an investigational drug and has not received regulatory approval.
However:
- The medication has received FDA Fast Track designation
- Regulatory submissions are expected following the OCEANIC-STROKE results
If approved, Asundexian could become an important addition to secondary stroke prevention strategies worldwide.
What This Means for Stroke Care
Stroke remains one of the leading causes of disability and death worldwide. Even after successful treatment of the first stroke, the risk of another event remains significant.
The OCEANIC-STROKE results suggest that Factor XI inhibition may offer a new strategy for preventing recurrent strokes without increasing bleeding risk.
If further studies confirm these findings and regulatory approval follows, Asundexian may become one of the most important new developments in stroke prevention in recent years.
For clinicians, this research highlights a potential future option for patients who currently have limited treatment choices after noncardioembolic ischemic stroke.
REFERENCE
1. Sharma M, Joundi R, Eikelboom J, et al. Factor XIa inhibition with asundexian in acute non-cardioembolic stroke or high-risk transient ischemic attack: primary results of the OCEANIC-STROKE trial. Presented at: International Stroke Conference 2026; February 4–6, 2026; New Orleans, LA. Abstract LB009.
2. Sharma M, Dong Q, Hirano T, et al. Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention. Eur Stroke J. 2026;11(1):aakaf017. doi: 10.1093/esj/aakaf017.3. Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400(10357):997–1007. doi: 10.1016/S0140-6736(22)01588-4.
